心肌炎
免疫系统
医学
免疫学
CD8型
外周血单个核细胞
T细胞
免疫分型
细胞毒性T细胞
生物
抗原
内科学
遗传学
体外
作者
Han Zhu,Francisco X. Galdos,Daniel Lee,Sarah Waliany,Yuhsin Vivian Huang,Julia Ryan,Katherine Dang,Joel W. Neal,Heather A. Wakelee,Sunil Reddy,Sandy Srinivas,Lih‐Ling Lin,Ronald Witteles,Holden T. Maecker,Mark M. Davis,Patricia K. Nguyen,Sean M. Wu
出处
期刊:Circulation
[Lippincott Williams & Wilkins]
日期:2022-07-25
卷期号:146 (4): 316-335
被引量:160
标识
DOI:10.1161/circulationaha.121.056730
摘要
BACKGROUND: Immune checkpoint inhibitors (ICIs) are monoclonal antibodies used to activate the immune system against tumor cells. Despite therapeutic benefits, ICIs have the potential to cause immune-related adverse events such as myocarditis, a rare but serious side effect with up to 50% mortality in affected patients. Histologically, patients with ICI myocarditis have lymphocytic infiltrates in the heart, implicating T cell-mediated mechanisms. However, the precise pathological immune subsets and molecular changes in ICI myocarditis are unknown. METHODS: (Murphy Roths large/programmed death-1-deficient) mice with spontaneous myocarditis. RESULTS: cells in both blood and hearts of such mice compared with controls. CONCLUSIONS: cells have unique transcriptional changes, including upregulation of chemokines CCL5/CCL4/CCL4L2, which may serve as attractive diagnostic/therapeutic targets for reducing life-threatening cardiac immune-related adverse events in ICI-treated patients with cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI